`
`MODIFIED ANTIBODIES
`
`Electronic Acknowledgement Receipt
`
`“—
`
`——
`
`
`
`——
`
`Payment information:
`
`Submitted with Payment
`
`no
`
`File Listing:
`
`Document
`Number
`
`Document Descri
`
`tion
`
`p
`
`File Size(Bytes)/
`Message Digest
`273045
`
`Pages
`Multi
`Part /.zip (if appl.)
`
`e283
`
`1
`
`52426-701-201_IDS.pdf
`
`847ac40c4c30d97e74382e79a3d4be4cf20
`
`
`
`Multipart Description/PDF files in .zip description
`
`Transmittal Letter
`
`Information Disclosure Statement (IDS) Form (SBO8)
`
`Foreign Reference
`
`WO12033953.PDF
`
`7565152
`
`4120f6b85f786c2603033937337314099d5
`139556
`
`2493917
`
`3437993599f726568ce534034d60837e4c0
`ccb84
`
`1369848
`
`cee0f35b2e38d767764672587ef1909e52b‘
`7631
`
`1121849
`
`05b26df9326f74a1803866301adeee7d0e6
`74613
`
`10225537
`
`6b9d33f7d3fed7252fac302869749c46ad29
`fcc6
`
`8884263
`
`d387
`
`- a
`
`Foreign Reference
`
`W02014193973A2.pdf
`
`Foreign Reference
`
`WO16004383.PDF
`
`Foreign Reference
`
`WO16011210.PDF
`
`Foreign Reference
`
`W02016036916A1.pdf
`
`Foreign Reference
`
`W02016138071A1.pdf
`
`b938dc5ce796ec1efdf06a7a3df72e83ee5e
`
`9'.o q3 W2 oF:
`
`”.o q3 W2 oF:
`
`- a
`
`”.o q3 W2 oF:
`
`lllllllilllll
`
`a”.o q3 W2 oF:
`
`9—,.O H3mm:1 OF:
`
`a”.o q3 W2 oF:
`
`-
`
`
`
`a”.o q3 W2 oF:
`
`8957425
`
`Foreign Reference
`
`W02016179003A1.PDF
`
`aObBBd17d835869cf50f9f67d32070c22dee
`885f
`
`a”.o q3 W2 oF:
`
`a”.o q3 W2 oF:
`
`Foreign Reference
`
`W02016200645A1.pdf
`
`3H6
`
`2950057
`
`406de805148fec183530b81398c461e7023‘
`83c3
`
`2084104
`
`9a4ab08c68fedff50282f9834e3006237314.
`877
`
`3943772
`
`6948ce4ce739b6263780432c5030259eca1
`e9188
`
`12214848
`
`_l O
`
`Foreign Reference
`
`WO17034615.PDF
`
`a”.o q3 W2 oF:
`
`|||||||||||||
`
`a”.o q3 W2 oF:
`
`Foreign Reference
`
`W02017075537A1.PDF
`
`_l N
`
`Non Patent Literature
`
`GRANT_MATRIGELINDUCES_36
`85—3694.PDF
`
`f0658e1e2ecda718df01760bc843c804e36 I
`
`a”.o q3 W2 oF:
`
`_l U)
`
`Non Patent Literature
`
`13102233
`
`LEGALL_IMMUNOSUPPRESSIVE
`_J|M_111_127_YEAR_2004_EF
`_P DF
`
`c8d184f443313d8fc08e95247ecb47c27ac5
`3f54
`
`a”.o q3 W2 oF:
`
`_x .b
`
`Non Patent Literature
`
`MURTAUGH_ACOMB|NATOR|A
`LH|ST|D|NESCANN|NG_1619—16
`3‘] _ P DF
`
`d9d511e10edeef0e070fe9f8397834dd93d
`
`9944960
`
`a”.o q3 W2 oF:
`
`
`
`2814988
`
`TAKEUCH|_ROLESOFTHEH|STID
`|NE_35—38.PDF
`
`b00b50c8e299c59483cfe64a4801lbc3579
`e1 166
`
`Non Patent Literature
`
`Information:
`
`Total Files Size (in bytes)
`
`87945998
`
`This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents,
`characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a
`Post Card, as described in MPEP 503.
`
`
`
`
`New Applications Under 35 U.S.C. 111
`If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR
`1.53(b)—(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this
`Acknowledgement Receipt will establish the filing date of the application.
`
`National Stage of an International Application under 35 U.S.C. 371
`If a timely submission to enter the national stage of an international application is compliant with the conditions of 35
`U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a
`national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`New International Application Filed with the USPTO as a Receiving Office
`If a new international application is being filed and the international application includes the necessary components for
`an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number
`and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning
`national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of
`the application.
`
`